Hispanics and Diabetes People with Hispanic or Latino backgrounds are at higher risk for developing type 2 diabetes than non-Hispanic Caucasians. This is a fact that researchers have long known. However, most research has looked at this group as a whole,…
¿Por qué es importante la diversidad en los ensayos clínicos?
Understanding the issue Clinical trials are the key to find and learn about the consequences of new medical treatments in people’s well-being. Some of them focus on patient’s safety and treatment effectiveness, others are just observational. These treatments include medicines, medical…
Marketing Strategies in Clinical Trials
It’s no secret that the recruitment process is often the most difficult part for a clinical trial. Just to give an example, let’s analyze a report from the Pharmaceutical Technology website. The report states that 15 – 20% of trials never…
Ministry of Health admits new regulation for Clinical Research in Peru
Friday, June 30, 2017, after two years, MINSA has issued a new regulation of clinical studies, through D.S. No. 021-2017-SA which replaces Supreme Decree No. 017-2006-SA and repeals D.S. N ° 020-2015-SA established the moratorium on clinical studies in the pediatric…
Clinical Trials in Latin America – Challenges and Opportunities
Latin America has become a great ally for clinicians when developing Clinical Trials. This region provides many advantages and facilities other regions just can’t match. With over 20 countries spanning from Mexico in North America to Chile and Argentina in the South….
5 obstáculos a los que te enfrentarás al diversificar los ensayos clínicos
Minority participation in clinical trials is an important topic in public health discussions. This representation touches on issues of equality and the elimination of disparities, which are core values of the field. The FDA Safety and Innovation Act introduced in 2012,…
6 Reasons to Diversify Clinical Trials
Starting from the fact that minorities account for fewer than 10 percent of patients enrolled in clinical trials. Health disparities and underrepresentation in clinical trials could become a serious issue in the upcoming years. FDA Regulations In 2012 Congress included Section…
Psoriatic Arthritis Drug Shows Promise in Phase 3 Trial
In a pivotal phase-3 clinical trial led by a Stanford University School of Medicine investigator, patients with psoriatic arthritis for whom standard-of-care pharmaceutical treatments have provided no lasting relief experienced a significant reduction in symptoms, including joint tenderness and swelling, when…
Clinical Trials Diversity – More Minorities Needed to Make Research Relevant to All
Minorities, in fact, account for fewer than 10 percent of patients enrolled in clinical trials, according to the National Institutes of Health (NIH) National Institute on Minority Health and Health Disparities. Today, Wilkins brings together academic researchers and community members to…
Clinical Research in Ecuador | Diversity in Hispanic Community Involvement
Why Is Diversity Important? FDA Action Plan In 2012 the Food and Drug Administration Safety and Innovation Act was published. Most of this FDA Action plan is based to encourage researchers to include safety and effectiveness data by demographic subgroups, including…